MAP2K7 and neuroblastoma: Interestingly, in some melanoma cell lines, treatment with the MEK inhibitor selumetinib (AZD6244) increased invasion in a spheroid assay [75], but the effects of MEK inhibition on neuroblastoma cell invasion has yet to be determined.